#ACR21 new 2022 classification criteria by ACR/EULAR for AAV 💥GPA-Sensitivity-92%, Specificity-94% 💥MPA-Sensitivity-91%, Specificity-94% 💥EGPA-Sensitivity-85%, Specificity-99% 💥Score based https://t.co/61SOl4Tovg

Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56

Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria https://t.co/YPc5fx9wAR #ACR21 Abst1945 @RheumNow

• Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined …

Retrospective chart review of rheumatic irAE patients: Persistent rheumatic irAE activity 🔼received GC Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp

Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs https://t.co/Id658ocDVf #ACR21 Abst1777 @RheumNow

• Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcom…

Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population 📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer @RheumNow #ACR21 https://t.co/4uQN6y3tIn

Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇 @RheumNow #ACR21 https://t.co/chmlGe4iyl

TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis 🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM @RheumNow #ACR21 https://t.co/rPg1CQuNka

Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke

• https://bit.ly/3qngYfx

JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21. https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS

• https://bit.ly/3bUKBfY

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus? https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T

• https://bit.ly/3mXArBA

AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently ⭐️🔽 clinic workload and better disease activity stratification Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk